HighTower Advisors’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$40.4M Buy
264,639
+13,264
+5% +$2.03M 0.04% 412
2025
Q4
$34.7M Sell
251,375
-1,828
-0.7% -$239K 0.04% 449
2025
Q3
$32.5M Buy
253,203
+10,543
+4% +$1.29M 0.04% 454
2025
Q2
$29.4M Buy
242,660
+4,819
+2% +$543K 0.04% 459
2025
Q1
$26.5M Buy
237,841
+2,488
+1% +$265K 0.04% 457
2024
Q4
$22.9M Sell
235,353
-55,507
-19% -$5.92M 0.03% 485
2024
Q3
$33.5M Sell
290,860
-4,988
-2% -$566K 0.05% 377
2024
Q2
$31.5M Sell
295,848
-405
-0.1% -$40.7K 0.05% 369
2024
Q1
$28.7M Buy
296,253
+7,284
+3% +$747K 0.05% 386
2023
Q4
$29.2M Buy
288,969
+6,369
+2% +$615K 0.05% 372
2023
Q3
$28.8M Buy
282,600
+19,435
+7% +$1.97M 0.05% 343
2023
Q2
$26.5M Buy
263,165
+11,116
+4% +$1.11M 0.05% 348
2023
Q1
$23.2M Buy
252,049
+5,610
+2% +$490K 0.05% 361
2022
Q4
$22.4M Buy
246,439
+2,200
+0.9% +$185K 0.05% 362
2022
Q3
$18.6M Buy
244,239
+614
+0.3% +$50.9K 0.05% 360
2022
Q2
$20.6M Sell
243,625
-56,517
-19% -$4.96M 0.05% 334
2022
Q1
$26.3M Sell
300,142
-6,051
-2% -$524K 0.06% 313
2021
Q4
$26.7M Sell
306,193
-2,332
-0.8% -$194K 0.06% 317
2021
Q3
$25.2M Sell
308,525
-3,340
-1% -$300K 0.07% 289
2021
Q2
$28.5M Buy
311,865
+12,734
+4% +$1.13M 0.08% 249
2021
Q1
$25.5M Buy
299,131
+15,942
+6% +$1.43M 0.08% 259
2020
Q4
$26.8M Buy
283,189
+39,934
+16% +$3.49M 0.11% 189
2020
Q3
$21.1M Buy
243,255
+25,153
+12% +$2.18M 0.1% 204
2020
Q2
$19M Sell
218,102
-1,311
-0.6% -$113K 0.1% 198
2020
Q1
$18M Sell
219,413
-3,257
-1% -$291K 0.12% 182
2019
Q4
$21.1M Buy
222,670
+4,539
+2% +$407K 0.12% 182
2019
Q3
$19M Buy
218,131
+4,536
+2% +$407K 0.1% 200
2019
Q2
$19.5M Sell
213,595
-4,228
-2% -$358K 0.12% 188
2019
Q1
$18.8M Sell
217,823
-625
-0.3% -$50.2K 0.13% 174
2018
Q4
$16.8M Buy
218,448
+7,050
+3% +$549K 0.13% 165
2018
Q3
$16.3M Sell
211,398
-5,280
-2% -$390K 0.12% 190
2018
Q2
$14.7M Sell
216,678
-5,958
-3% -$411K 0.12% 199
2018
Q1
$16.1M Sell
222,636
-21,153
-9% -$1.61M 0.14% 167
2017
Q4
$18.3M Sell
243,789
-40,855
-14% -$3.08M 0.15% 142
2017
Q3
$21.9M Sell
284,644
-1,466
-0.5% -$111K 0.19% 116
2017
Q2
$21.4M Buy
286,110
+1,680
+0.6% +$119K 0.19% 113
2017
Q1
$18.9M Buy
284,430
+9,471
+3% +$631K 0.18% 118
2016
Q4
$17.9M Sell
274,959
-16,573
-6% -$1.08M 0.19% 105
2016
Q3
$20.6M Buy
291,532
+8,938
+3% +$651K 0.24% 88
2016
Q2
$20.9M Sell
282,594
-60,017
-18% -$4.15M 0.26% 80
2016
Q1
$22.2M Buy
342,611
+10,951
+3% +$745K 0.07% 97
2015
Q4
$25.6M Buy
331,660
+28,711
+9% +$2.28M 0.3% 69
2015
Q3
$25M Sell
302,949
-10,484
-3% -$933K 0.33% 64
2015
Q2
$27.6M Buy
313,433
+7,234
+2% +$664K 0.44% 40
2015
Q1
$27.1M Buy
306,199
+2,170
+0.7% +$192K 0.4% 47
2014
Q4
$25.2M Buy
304,029
+3,886
+1% +$322K 0.39% 47
2014
Q3
$25.3M Buy
300,143
+10,625
+4% +$860K 0.43% 40
2014
Q2
$23.5M Buy
289,518
+7,784
+3% +$612K 0.41% 46
2014
Q1
$21.5M Buy
281,734
+89,449
+47% +$6.52M 0.42% 45
2013
Q4
$13.8M Buy
192,285
+7,913
+4% +$550K 0.28% 74
2013
Q3
$12.7M Buy
184,372
+2,682
+1% +$177K 0.32% 69
2013
Q2
$11.6M Buy
+181,690
New +$11.8M 0.32% 66

Other funds holding NVS

HighTower Advisors's NVS Position: Q1 2026 in Review

HighTower Advisors increased its Novartis (NVS) stake by 5.3% in Q1 2026, buying an estimated $2.03M and bringing the position to 264,639 shares worth $40.4M. The position accounts for 0.04% of the portfolio, ranked #412.

HighTower Advisors first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. 1,591 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • HighTower Advisors held 264,639 shares of Novartis worth $40.4M as of Q1 2026.
  • HighTower Advisors bought 13,264 Novartis shares in Q1 2026, an estimated $2.03M.
  • Novartis made up 0.04% of HighTower Advisors's portfolio in Q1 2026, its #412 holding.
  • HighTower Advisors first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
  • 1,591 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.